Document Detail

Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection.
MedLine Citation:
PMID:  23238684     Owner:  NLM     Status:  Publisher    
The purpose of this study was to evaluate the cost-effectiveness of the strategy of controlling the contacts of tuberculosis patients with latent tuberculosis infection by means of treatment with rifampin for 4 months or isoniazid for 9 months. The cost was the sum of the cost of treating latent tuberculosis infection in all contacts plus the cost of treating tuberculosis in whom the disease was not avoided. The effectiveness was expressed as cases avoided. The efficacy adopted was 90 % for rifampin for 4 months and 93 % for isoniazid for 9 months. We carried out a sensitivity analysis for efficacies of rifampin for 4 months of 80 %, 75 %, 69 % and 65 %. Of the 1,002 patients studied, 139 were treated with rifampin for 4 months and 863 were treated with isoniazid for 9 months. The cost-effectiveness was <euro>436,842.83/50 cases avoided with rifampin for 4 months and <euro>692,164.42/40 cases avoided with isoniazid for 9 months. Rifampin for 4 months was dominant. In the sensitivity analysis, rifampin for 4 months was dominant for efficacies of 75 % or greater. The cost-effectiveness analysis favoured the use of rifampin for 4 months when its efficacy was 75 % or greater.
J M Pina; L Clotet; A Ferrer; M R Sala; P Garrido; L Salleras; A Domínguez
Related Documents :
25072244 - Pattern of statin use in southern italian primary care: can prescription databases be u...
23351964 - Positive effect of septimeb™ on mortality rate in severe sepsis: a novel non antibiot...
24268304 - "first look" unsedated transnasal esogastroduodenoscopy in patients with upper gastroin...
24974994 - Effectiveness of 3 methods of anchorage reinforcement for maximum anchorage in adolesce...
23938124 - Postoperative optical coherence tomographic appearance and relation to visual acuity af...
18848674 - Clinical changes of patients with cystic fibrosis during transition from pediatric to a...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-13
Journal Detail:
Title:  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology     Volume:  -     ISSN:  1435-4373     ISO Abbreviation:  Eur. J. Clin. Microbiol. Infect. Dis.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8804297     Medline TA:  Eur J Clin Microbiol Infect Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Catalan Health Institute (ICS), Department of Health, Generalitat of Catalonia, Catalonia, Spain,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Next Document:  Which patients should be tested for viruses on bronchoalveolar lavage fluid?